APO T B V has a total of 44 patent applications. It decreased the IP activity by 25.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), Australia and United States. Its main competitors in its focus markets pharmaceuticals and biotechnology are PIERIS AUSTRALIA PTY LTD, ABEXXA BIOLOGICS INC and TON LOGTENBERG.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 11 | |
#2 | Australia | 10 | |
#3 | United States | 9 | |
#4 | Canada | 6 | |
#5 | WIPO (World Intellectual Property Organization) | 6 | |
#6 | New Zealand | 1 | |
#7 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Willemsen Ralph Alexander | 40 |
#2 | Renes Johan | 38 |
#3 | Steverink Paul | 15 |
#4 | Kijanka Marta | 4 |
#5 | Steverink Paulus J | 3 |
#6 | Steverink Paulus Johannes Gerardus Maria | 2 |
#7 | Steverink Paulus J G M | 1 |
Publication | Filing date | Title |
---|---|---|
CA3102254A1 | Methods and means for attracting immune effector cells to tumor cells | |
US2015175683A1 | Binding molecules targeting pathogens | |
NZ722167A | Binding molecules targeting pathogens | |
AU2013208364A1 | Aberrant cell-restricted immunoglobulins provided with a toxic moiety | |
WO2013048243A1 | Multi-specific binding molecules targeting aberrant cells | |
AU2011353197A1 | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
EP2658872A1 | A polypeptide that binds aberrant cells and induces apoptosis |